Recent Research Analysts’ Ratings Changes for NovoCure (NVCR)

A number of research firms have changed their ratings and price targets for NovoCure (NASDAQ: NVCR):

  • 4/28/2021 – NovoCure was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 4/26/2021 – NovoCure had its price target raised by analysts at Truist Securities from $132.00 to $142.00. They now have a “hold” rating on the stock.
  • 4/20/2021 – NovoCure had its “underperform” rating reaffirmed by analysts at Wedbush. They now have a $154.00 price target on the stock, down previously from $159.00.
  • 4/20/2021 – NovoCure had its price target raised by analysts at Northland Securities from $200.00 to $250.00. They now have an “outperform” rating on the stock.
  • 4/20/2021 – NovoCure had its price target raised by analysts at Mizuho from $175.00 to $242.00. They now have a “buy” rating on the stock.
  • 4/19/2021 – NovoCure had its price target raised by analysts at Truist Securities from $132.00 to $142.00. They now have a “hold” rating on the stock.
  • 4/19/2021 – NovoCure had its price target raised by analysts at Truist from $132.00 to $142.00.
  • 4/17/2021 – NovoCure was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 4/14/2021 – NovoCure was downgraded by analysts at Wedbush from a “neutral” rating to an “underperform” rating. They now have a $154.00 price target on the stock, down previously from $159.00.
  • 4/14/2021 – NovoCure had its price target raised by analysts at Northland Securities from $200.00 to $250.00. They now have an “outperform” rating on the stock.
  • 4/14/2021 – NovoCure had its price target raised by analysts at Mizuho from $175.00 to $242.00. They now have a “buy” rating on the stock.
  • 4/13/2021 – NovoCure had its price target raised by analysts at Wells Fargo & Company from $135.00 to $215.00. They now have an “equal weight” rating on the stock.
  • 4/10/2021 – NovoCure was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 4/1/2021 – NovoCure was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 3/17/2021 – NovoCure was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. “
  • 3/8/2021 – NovoCure had its price target raised by analysts at Mizuho from $150.00 to $175.00. They now have a “buy” rating on the stock.

NVCR stock traded down $5.30 during mid-day trading on Tuesday, hitting $197.26. 30,741 shares of the company were exchanged, compared to its average volume of 973,395. NovoCure Limited has a 1-year low of $55.40 and a 1-year high of $220.48. The firm has a market cap of $20.20 billion, a P/E ratio of 1,038.27 and a beta of 1.29. The firm’s 50 day simple moving average is $160.67 and its 200 day simple moving average is $154.29.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, April 29th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.06). NovoCure had a net margin of 4.26% and a return on equity of 7.40%. On average, equities research analysts forecast that NovoCure Limited will post 0.23 EPS for the current fiscal year.

In related news, Chairman William F. Doyle sold 7,928 shares of the firm’s stock in a transaction on Thursday, April 1st. The shares were sold at an average price of $134.12, for a total value of $1,063,303.36. Following the completion of the transaction, the chairman now directly owns 658,321 shares of the company’s stock, valued at $88,294,012.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Asaf Danziger sold 97,973 shares of the firm’s stock in a transaction on Tuesday, April 13th. The shares were sold at an average price of $196.34, for a total transaction of $19,236,018.82. The disclosure for this sale can be found here. Insiders sold 216,529 shares of company stock worth $41,906,260 over the last quarter. 5.07% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. grew its stake in shares of NovoCure by 18.5% in the first quarter. Victory Capital Management Inc. now owns 534,062 shares of the medical equipment provider’s stock valued at $70,592,000 after buying an additional 83,276 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in shares of NovoCure by 67.4% in the first quarter. Daiwa Securities Group Inc. now owns 9,728 shares of the medical equipment provider’s stock valued at $1,286,000 after buying an additional 3,916 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of NovoCure by 39.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,110 shares of the medical equipment provider’s stock valued at $2,658,000 after buying an additional 5,714 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in shares of NovoCure in the first quarter valued at $64,000. Finally, Meeder Asset Management Inc. grew its stake in shares of NovoCure by 127,400.0% in the first quarter. Meeder Asset Management Inc. now owns 1,275 shares of the medical equipment provider’s stock valued at $168,000 after buying an additional 1,274 shares in the last quarter. 71.09% of the stock is owned by institutional investors and hedge funds.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.

See Also: Gap Up Stocks

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.